09 Dec The SLIM LIVER Study
It is estimated that 30-40% of adults living with HIV have non-alcoholic fatty liver disease (NAFLD). NAFLD is the buildup of extra fat in the liver cells that is not caused by alcohol.
Treating NAFLD may have far-reaching benefits, including reduction of insulin resistance and prevention or treatment of cardiovascular disease, which is often associated with NAFLD.
The SLIM LIVER Study will investigate the effects of a drug called semaglutide to see if it will reduce liver fat in people with HIV and if it has any effect on factors that are associated with the development of fatty liver disease.
Semaglutide will be given once a week as a self-injection for 24 weeks. Participants will be followed for an additional 24 weeks after stopping the study drug.
- All people with HIV
- Ages 18 and older
- No change in HIV medicine in 24 weeks
- Undetectable HIV viral load for 24 weeks
- Have fatty liver disease (diagnosed by imaging at a pre-entry visit)
- CD4 T cell count of at least 200
- No diabetes
- No heavy drinking (alcoholic drinks)
- No current hepatitis B or C
Eli Burnham, PA-C
Additional Study Details
Full Study Title
A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk
Rachel Bender Ignacio, Liz Duke
Accepts Healthy Volunteers?
Harborview Medical Center
325 9th Ave 2nd floor of the 2 West Clinics
Seattle, Washington 98104